Precefi, Inc. is pleased to announce that its poster, “Need for a Tolerable and Efficacious Topical Molluscum Contagiosum Drug for Pediatric Use,” was featured at the 25th European Society for Pediatric Dermatology (ESPD) Congress, held April 28-30, 2026 in Padova, Italy.
The poster examines the clinical limitations of the two FDA-approved topical therapies currently available for pediatric molluscum contagiosum (MC), topical cantharidin 0.7% and topical berdazimer gel 10.3%, and makes the case for a significant unmet medical need in one of the most common pediatric skin conditions.
Despite a U.S. patient population in the millions and pediatric prevalence reaching 5.1%–11.5%, neither approved topical has emerged as a clear first-line standard of care. Trade-offs in efficacy, tolerability, administration, and cost continue to leave families and clinicians without an ideal therapeutic option, with watchful waiting still common for lesions that can persist up to 36 months untreated.
The poster concludes that a topical pediatric MC product combining strong efficacy, tolerability, and convenient at-home administration represents a clear development opportunity and reinforces Precefi’s commitment to advancing dermatology programs that close gaps like this one.
